Sapient Therapeutics Announces Positive Phase 1 Results in Part B of Its Solid Dose Prescription CBD Study

Contributed by: Business Wire

Tags

Alternative Medicine

Health

Clinical Trials

Research

Science

Pharmaceutical

Biotechnology

neuroscience

More Like This

Avata Biosciences Emerges to Develop Solid Dose Cannabinoid Medicines for Epilepsy and Other Neurological Diseases

CBD is approved for treatment-resistant epilepsy in children, and recent trials suggest that it may be useful for treating other disorders, such as schizophrenia and anxiety. Photo credit: Julia Zolotova

Quolet announces completion of Phase 1 healthy volunteer study evaluating the safety and bioavailability of Cannabidiol in a novel formulation intended for treatment of various neurological and psychiatric diseases

Brains Bioceutical Set to Achieve One of the World’s First CEP for Cannabidiol Certification with the European Directorate for the Quality of Medicines & Healthcare

Brains Bioceutical Expands Industry-Leading Cannabinoid Offering with D9-THC and CBN, Unveiling New Frontiers for Drug Development

Tilray Medical Publishes Pioneering Research on the Pharmacokinetics of THC and CBD Formulations

Avata Biosciences Signs Co-Development and Licensing Agreement with Oceanus Bio for Exclusive Rights in Japan and Asia (Excluding China and India) for Novel Adult and Pediatric Oral Cannabidiol Therapies for Development in Epilepsy and Schizophrenia

(Photo: Business Wire)

ANANDA Scientific Announces a Clinical Trial Evaluating Nantheia™ ATL5, in the treatment of Co-Occurring Opioid Use Disorder and Chronic Pain

PR Newswire associated0

Indivior Provides Update on Aelis Farma's Clinical Phase 2B Study Results with AEF0117 in Participants with Cannabis Use Disorder